Skip to main content

Table 2 Incidence and duration of secondary outcomes within 60 days of hematopoietic stem cell transplantation in the two groups of study patients

From: Effect of vitamin A on intestinal mucosal injury in pediatric patients receiving hematopoietic stem cell transplantation and chemotherapy: a quasai-randomized trial

Outcomes Study groups P value
Vitamin A supplementation (n = 15) Non-vitamin A supplementation (n = 15)
Febrile neutropenia, n (%) 11 (73.3) 11 (73.3) 1
Oral mucositis, n (%) 14 (93.3) 15 (100) 1
Oral mucositis severity grade 3–4, n (%) 6 (40) 9 (60) 0.27
Diarrhea, n (%) 14 (93.3) 14 (93.3) 1
Hemorrhagic cystitis, n (%) 5 (33.3) 5 (33.3) 1
Graft-versus-host disease, n (%) 6 (40) 7 (46.7) 1
Bacterial infection, n (%) 1 (6.7) 2 (13.3) 1
Viral infection, n (%) 10 (66.7) 6 (40) 0.14
Day of neutrophil engraftment, mean days ± SD 14 ± 2.8 14.2 ± 3.9 0.87
Duration of febrile neutropeniaa, days 5 (2–10) 6.5 (1–21) 0.8
Duration of mucositis, mean days ± SD 9 ± 3.8 9 ± 4.7 0.96
Duration of diarrheaa, days 11.5 (2–44) 15.5 (2–37) 0.42
Duration of need of TPN, days ± SD 13 ± 7.1 11 ± 6.6 0.42
Duration of hospitalization after day 0a, days 29 (18–83) 24 (15–54) 0.13
Mortality, n (%) 0 2 (13.3) 0.48
  1. aMedian (min–max)
  2. SD standard deviation, TPN total parenteral nutrition